Receptors for luteinizing hormone-releasing hormone (GnRH) as therapeutic targets in triple negative breast cancers (TNBC).

Kwok, C W; Treeck, O; Buchholz, S; Seitz, S; Ortmann, O; Engel, J B

Kwok, C W; Treeck, O; Buchholz, S; Seitz, S; Ortmann, O; Engel, J B.

Affiliation

Kwok CW; Department of Gynecology and Obstetrics, University Medical Center Regensburg, 93053, Regensburg, Germany.

Target Oncol ; 10(3): 365-73, 2015 Sep.

Article in En | MEDLINE | ID: mdl-25293576

Subject(s)

Breast Neoplasms/metabolism; Gene Expression Regulation, Neoplastic; Gonadotropin-Releasing Hormone/agonists; Gonadotropin-Releasing Hormone/chemistry; Triple Negative Breast Neoplasms/metabolism; Aniline Compounds/therapeutic use; Antineoplastic Agents/chemistry; Antineoplastic Combined Chemotherapy Protocols/therapeutic use; Breast Neoplasms/drug therapy; Cell Line, Tumor; Cell Proliferation; Cisplatin/therapeutic use; DNA Mutational Analysis; Dose-Response Relationship, Drug; Drug Synergism; Female; Humans; Phosphatidylinositol 3-Kinases/metabolism; Phosphorylcholine/analogs & derivatives; Phosphorylcholine/therapeutic use; Receptors, LHRH/metabolism; Triptorelin Pamoate/therapeutic use

Fulltext

XML

PubMed Links

Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Breast Neoplasms / Gene Expression Regulation, Neoplastic / Gonadotropin-Releasing Hormone / Triple Negative Breast Neoplasms Type of study: Prognostic_studies Limits: Female / Humans Language: En Journal: Target Oncol Year: 2015 Document type: Article

Fulltext

XML

PubMed Links

Search on Google